Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 94.88B 86.53B 80.01B 72.2B 136B 8,866B 141B 966B 382B 4,786B 356B 349B 15,112B P/E 2026 *
16x
P/E 2027 * 15.2x
Enterprise Value 87.71B 80B 73.96B 66.75B 126B 8,197B 131B 893B 353B 4,424B 329B 322B 13,970B EV / Sales 2026 *
4.66x
EV / Sales 2027 * 4.08x
Free-Float
72.51%
Yield 2026 *
0.4%
Yield 2027 * 0.42%
1 day-1.28%
1 week-1.45%
Current month+1.90%
1 month+19.58%
3 months+16.70%
6 months+50.16%
Current year+22.50%
1 week 942
Extreme 942
972.24
1 month 789.69
Extreme 789.69
991.73
Current year 591.52
Extreme 591.52
991.73
1 year 591.52
Extreme 591.52
991.73
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

SVP Controller

11,828 0.0117%
3/11/26 Exercice

Director

22,317 0.0221%
3/11/26 Don

Chief Technology Officer

-1,054 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-1.45%+30.36%+17.83% 94.88B
-2.32%-3.79%+34.24%+133.69% 1,232B
-2.15%-2.75%+36.35%+82.05% 656B
-2.33%-3.04%+22.29%+106.80% 506B
-0.83%-1.57%+28.98%+68.71% 382B
-3.90%-6.39%+42.88%+35.41% 340B
-3.12%-5.20%+24.48%+50.97% 294B
-1.47%-3.37%-1.00%+33.19% 278B
-3.07%-5.17%+29.04%+67.26% 240B
-0.75%-0.44%+32.87%+123.96% 210B
Average -1.26%-2.22%+28.05%+71.99% 423B
Weighted average by Cap. -1.38%-2.64%+29.91%+89.51%

Financials

2026 *2027 *
Net sales 18.81B 17.16B 15.87B 14.32B 26.97B 1,758B 28.03B 192B 75.74B 949B 70.59B 69.11B 2,997B 20.17B 18.39B 17.01B 15.35B 28.9B 1,885B 30.04B 205B 81.19B 1,017B 75.66B 74.07B 3,212B
Net income 6.43B 5.86B 5.42B 4.89B 9.21B 601B 9.57B 65.45B 25.87B 324B 24.11B 23.6B 1,024B 6.56B 5.98B 5.53B 4.99B 9.4B 613B 9.77B 66.8B 26.41B 331B 24.61B 24.09B 1,045B
Net Debt -7.17B -6.54B -6.04B -5.45B -10.27B -670B -10.68B -73B -28.86B -362B -26.89B -26.33B -1,142B -12.52B -11.42B -10.55B -9.53B -17.94B -1,170B -18.65B -127B -50.39B -631B -46.96B -45.98B -1,994B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
18/11/26 US$945.53 -1.28% 705,406
17/11/26 US$957.76 +0.56% 933,408
16/11/26 US$952.40 -0.32% 700,861
13/11/26 US$955.47 +0.45% 1,165,717
12/11/26 US$951.19 -0.86% 1,211,308
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
945.53USD
Average target price
990.81USD
Spread / Average Target
+4.79%
  1. Stock Market
  2. Stocks
  3. REGN Stock